Stocks · News reference
BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc Disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
BioRestorative Therapies Announces 1-For-20 Reverse Stock Split
BioRestorative Therapies, Inc. (NASDAQ:BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a
8-K filing — BioRestorative Therapies, Inc. (BRTX)
Filed: 2026-09-02 AccNo: 0001213900-26-096810 Size: 235 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits